Sinomab BioScience Limited released its Monthly Return for Equity Issuers for the period ended 30 June 2026, confirming no change in its issued share capital and continued compliance with Hong Kong’s public-float requirements.

• Issued Shares Unchanged: The company’s ordinary shares in issue remained at 1.39 billion (1,386.64 million) with no treasury shares on record. No new shares were allotted, repurchased, or cancelled during the month.

• Public-Float Compliance: As at 30 June 2026, the free-float exceeded the Main Board’s 25% threshold, ensuring trading liquidity on the Hong Kong Stock Exchange.

• Share Option Movements: Under the 2022 Share Option Scheme, 11.09 million options lapsed, reducing outstanding options to 69.49 million. No options were exercised; consequently, no funds were raised and no shares were issued. The scheme still permits up to 16.93 million shares to be issued from existing options, with a further 52.05 million shares available for grant.

• No Activity in Other Equity Instruments: The company reported no movements involving warrants, convertible securities, other share-issuance agreements, or treasury shares.

The filing was authorised by Executive Director, Chairman and Chief Executive Officer Shui On Leung on 7 July 2026.